Jiangsu Zhongdao Xintian Pharmaceutical

Jiangsu Zhongdao Xintian Pharmaceutical is a clinical-stage biotechnology company based in Nanjing, China, focused on the development of innovative small molecule targeted therapies for cancer. The company's primary research efforts are directed toward addressing unmet needs in oncology, particularly in the treatment of non-small cell lung cancer and other solid tumors. Its lead candidate, ZD001, is a potent multi-target inhibitor of ALK, ROS1, and c-MET currently undergoing Phase 2 clinical trials. Additionally, the company is advancing ZD003, a KRAS G12C inhibitor, through early-stage clinical development. Zhongdao Xintian leverages its internal R&D expertise to create a pipeline of high-potential oncology assets. The company aims to provide high-quality, affordable innovative medicines to patients globally through its integrated R&D platform.